Cross tables with clinicopathological characteristics versus ITIH2 staining were established, using Fisher's exact test (two-sided) to evaluate significancy.
After washing, tissue sections were mounted with an anti-fading solution containing 4′-6-diamidino-2-phenylindole (DAPI Vector Laboratoriess, Burlingame, CA) and negative control staining were established by omitting the primary antibodies.
Specificity of the immunofluorescent staining reaction was established by failure to obtain staining with normal serum, with smooth muscle antibody serum neutralized by homogenates of smooth muscle or extracts containing actin derived from smooth muscle.
A double immunofluorescence staining procedure was established for the identification of cytokeratin (CK) positive/Erα-positive cells.
Specificity of the staining reaction was established by its prevention on neutralization absorptions of the serum with extracts or homogeneous of smooth muscle.
To compare this staining with the occurrence of NSE in serum, a histological staining index (HSI) was established by semiquantitative gradation of the staining.
BAX staining index (BSI) was established based on information on both staining intensity and the percentage of positive cells within a tumour.
The specificity of staining in FCM was established by using non-specific mouse IgG1 and unlabelled Dex.
The significance of CX3CR1 staining of TMAs was established by a two-tailed Fisher's exact test performed using GraphPad Prism and using the method of summing small P-values.
